2018 started with a whirlwind of hope after the December announcement from Ionis that their trial of the Huntingtin Lowering drug Ionis-HTTRx was safe and well tolerated. In Feb 2018 our Chairperson BJ Viau represented HDYO at the CHDI Palm Springs Therapeutics conference where the data from the trial was being presented by Prof Sarah Tabrizi.

Here is the video from the conferences with all the information about the latest research and opportunities, including an interview with BJ and a very brief appearance by Cat.

The main message is that the whirlwind looks likely to continue but for now we need to be patient, manage our expectations and get involved in anyway you can.